GustavoAlvaMDDFAPA

Founder and Medical Director of ATP Clinical Research

Dr. Alva is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3151 Airway Ave Ste T3
Costa Mesa, CA 92626
Phone+1 833-487-2582

Fax+1 714-545-5748

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
Completed
Phase 2, Phase 3
A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease Start of enrollment: 2017 May 09
Completed
Phase 1, Phase 2
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Start of enrollment: 2022 Nov 01
Recruiting
Phase 3
Roles: Contact, Principal Investigator
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD Start of enrollment: 2021 Jun 21
Completed
Phase 1
Roles: Contact, Principal Investigator
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Start of enrollment: 2021 Nov 03
Active, not recruiting
Phase 3
Roles: Principal Investigator, Contact
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease Start of enrollment: 2022 May 12
Active, not recruiting
Phase 2, Phase 3
Roles: Contact
ANC-501 in the Treatment of Adults With Major Depressive Disorder Start of enrollment: 2022 Sep 19
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

PubMed

(6-Month Paliperidone Palmitate), First and Only Twice-Yearly Treatment for Adults with SchizophreniaSeptember 1st, 2021
Dollars for Docs Mints a MillionaireMarch 11th, 2013
Regeneration Bio Commences Trial of Alzheimer’s Stem Cell Therapy Delivered Directly into the BrainMay 7th, 2024